HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Limited Brands

This article was originally published in The Rose Sheet

Executive Summary

After adjusting for lease accounting methods, fourth quarter results are less than previously reported, firm announces in final Q4 and year-end results April 11. As a result of a review, the company has taken a one-time pretax charge of $61 mil. to correct its accounting for "straight-line rent and the depreciation and amortization of leasehold improvements and certain landlord allowances," company notes. As a result, fourth quarter net earnings fell 1.3% to $382.5 mil. and net earnings for the year declined 1.6% to $705.4 mil. In February, the firm reported preliminary results with net earnings in Q4 up 7% to $415.8 mil. and 2004 net income growing 3.1% to $738.7 mil. (1"The Rose Sheet" Feb. 28, 2005, p. 7). Sales and other related items are not impacted by the adjustment, company notes...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel